AAV Based Combination Therapies to Improve Glioblastoma Treatment Efficacy
CWSF · 2026 Disease & Illness
Overview
Glioblastoma is one of the most aggressive forms of brain cancer with a 5-year survival rate of less than 10%. My project focused on using Adeno-Associated Virus (AAV) as a vessel for gene therapy in combination with immunotherapy or chemotherapy to make the treatment more effective than monotherapies, such as only chemotherapy, radiation therapy, or surgery, when treating Glioblastoma. I compiled data from existing studies that focused on one strategy for using AAV combination therapies to compare the effectiveness of the treatments. The treatment strategies included enabling the immune system to recognize the cancer, getting the cancer cells to self-destruct, and driving the tumour cells to turn into neuron cells. I found that these therapies can reduce tumour mass and cell viability, and improve survival rates. These findings are significant because they could lead to more effective and targeted treatments, giving patients a better chance at survival.
Awards (1)
- Selected for CWSF 2026
Competition history
- CWSF 2026
Related projects
ISEF · 2023
Innovative Combination Therapy for Treating Brain Tumors: Using Avatar Models to Help Improve Patient Outcomes
ISEF · 2020
Designing a Tumor-Specific Oncolytic Virus to Induce Suicide Gene Expression
CWSF · 2026
Brain-Penetrating Bioconjugate M13-CTX-PEP-1 for Targeted Glioblastoma Therapy In Silico
ISEF · 2026
GCORE: Glioblastoma-Related Chimeric Antigen Receptor T Cell Therapy Outcome Re-Engineering
Closest projects by meaning, across every fair and year in the corpus.